Scribe Therapeutics Director OrbiMed Advisors Buys $15M Stock

What Happened
OrbiMed Advisors LLC (reported as a director-related reporting person) purchased 1,000,000 shares of Scribe Therapeutics (SCTX) in the company’s IPO on July 27, 2026 at $15.00 per share for $15,000,000. On the same date OrbiMed’s holding company converted 2,065,672 shares of Series B Preferred Stock into 348,825 shares of common stock pursuant to the IPO closing (automatic one-for-0.1689 conversion), at no cash consideration. Net new common shares received that day: 1,348,825 (1,000,000 IPO purchase + 348,825 conversion).

Key Details

• Transaction date: July 27, 2026; Form 4 filed July 29, 2026 (within usual 2-business-day window).
• Open-market/IPO purchase: 1,000,000 shares at $15.00 each = $15,000,000 (footnote F2: reflects shares purchased in the IPO).
• Conversion: 2,065,672 Series B Preferred converted into 348,825 common shares (one-for-0.1689 ratio) without payment upon IPO closing (footnote F1). The derivative entry shows the preferred shares were disposed/converted and common shares acquired.
• Holdings structure: Shares are held by OrbiMed Private Investments VIII, LP (OPI VIII); OrbiMed Advisors, as managing member of the GP, may be deemed to have voting/investment power (footnote F3). Carl L. Gordon was designated as the issuer board representative (footnote F4).
• Shares owned after transaction: not specified in the excerpted transactions on this filing; refer to the full Form 4 for total post-transaction beneficial ownership.
• Filing timeliness: No late filing indicated; reported within two business days.

Context

• This filing documents an institutional investor (OrbiMed-related entities) participating in the IPO and the automatic conversion of preferred stock into common on the IPO close. Purchases in an IPO are often viewed as a stronger signal than routine sales, but filings are factual records and do not state motives.
• The conversion entries reflect elimination of the preferred/derivative position and issuance of common stock under the stated conversion ratio, not an exercise or cash transaction.